Health Care System (4th ed San Francisco, CA: Jossey-Bass, 2013.
Comanor WS and Schweitzer SO, eds., Readings in Pharmaceutical Economics and Policy, (Cheltenham UK: Edward Elgar Publishers 2014 (in press).
Scott Morton (1999 Entry Decisions in the Generic Pharmaceutical Industry.
Danzon, Andrew Epstein and Sean Nicholson (2007 Mergers and Acquisitions in the Pharmaceutical and Biotech Industries.Most fm 2005 editor 2013 offline chapters include numerous figures and graphs and all are well referenced for those who wish to explore the topics further.This third edition of a uniquely comprehensive and balanced examination of the industry includes several new chapters on important topics such as the full-fledged generics sector, the arrival of biosimilars or generic biological drugs, the global consolidation of manufacturers, the evolving reimbursement landscape, and the.Amer J Public Health, June 2013.This book is an essential edition to libraries in colleges of pharmacy and medicine as well as other large, academic health centers.The book does a very good job of covering each of these subjects and reviewing relevant policy studies, data, and theory relevant to each.Salkever (1997 Generic Entry and the Pricing of Pharmaceuticals.Foremost among these is the author's clear explanations of the wide array of diverse topic areas covered in the book.Schweitzer with Karleen Giannitrapani.
The Economic Importance of Intangible Assets, London: Ashgate, 2005.
The text should prove invaluable to students from a variety of disciplines and to faculty members teaching in professional and graduate courses dealing with the many policy issues that surround the structure, conduct, and performance of the prescription drug industry).
Di Tommaso, MR, Schweitzer,.O., "Intangible Clusters of Firms in Bianchi P and Labory S (eds.A major strength of, pharmaceutical Economics and Policy is the fact that it covers nearly all of the major topic areas that might be covered in a graduate course devoted to the topic.The first section of the text contains 4 chapters devoted to explicating the structure and conduct of the pharmaceutical industry.Schweitzer's treatment of each topic area is even-handed and empirically based.Pharmaceuticals constitute a relatively small share of the total healthcare expenditure in most developed economies, and yet they play a critical role in the ongoing debate over how best to advance, improve, and afford healthcare.Chapters carried over from the first edition have been entirely updated and most have been expanded, with the second edition running nearly 100 pages longer than the previous edition.DiTommaso MR and Schweitzer SO (eds International Journal of Healthcare Technology and Management 11(4) (Special Issue on University-Industry Technology Transfer in the High-Technology Sector 2010.Di Tommaso.R and Schweitzer SO, Industrial policy in America: Breaking the taboo, (Cheltenham UK: Edward Elgar Publishers 2013.Hurwitz (1991 Patent Expiration, Entry, and Competition in the.S.Schweitzer SO, Introduction: How will health systems adopt new genetics technology? .Comanor (2007 The Economics of Research and Development in the Pharmaceutical Industry.
The analytical tools of economics provide a strong foundation for a better understanding of the dynamics of the pharmaceutical industry, its contribution to health and healthcare, its dual and often conflicting priorities of affordability and innovation, as well as the various private and public policy.
Henry Grabowski, John Vernon and Joseph.